Mostrar el registro sencillo del ítem
Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment
dc.contributor.author | Sarabia de Ardanaz, Luis | |
dc.contributor.author | Andreu Ubero, José María | |
dc.contributor.author | Navidad Fuentes, Miriam | |
dc.contributor.author | Ferrer González, Miguel Ángel | |
dc.contributor.author | Ruiz del Valle, Víctor | |
dc.contributor.author | Salcedo Bellido, Inmaculada | |
dc.contributor.author | Barrios Rodríguez, Rocío | |
dc.contributor.author | Cáliz Cáliz, Antonio Rafael | |
dc.contributor.author | Requena Méndez, María del Pilar | |
dc.date.accessioned | 2021-09-14T10:15:58Z | |
dc.date.available | 2021-09-14T10:15:58Z | |
dc.date.issued | 2021-07-01 | |
dc.identifier.citation | Sarabia De Ardanaz L... [et al.] (2021) Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment. Front. Pharmacol. 12:620187. doi: [10.3389/fphar.2021.620187] | es_ES |
dc.identifier.uri | http://hdl.handle.net/10481/70202 | |
dc.description | We thank Pablo Lardelli Claret for his helpful advice in statistical methods. We also acknowledge the staff of Hospital Universitario Virgen de las Nieves who took (and are taking) care of the COVID-19 patients. | es_ES |
dc.description.abstract | Tocilizumab (TCZ) has been administered in SARS-CoV-2 pneumonia but the factors associated with mortality before and after treatment remain unclear. Cox regression models were used to estimate the predictors of time to death in a cohort of hospitalized patients with COVID-19 receiving TCZ. In addition, the mean differences between discharged and deceased patients in laboratory parameters measured before and 3, 6 and 9 days after TCZ administration were estimated with weighted generalized estimation equations. The variables associated with time to death were immunosuppression (Hazard Ratio-HR 3.15; 95% confidence interval-CI 1.17, 8.51), diabetes mellitus (HR 2.63; 95% CI 1.23–5.64), age (HR 1.05; 95% CI 1.02–1.09), days since diagnosis until TCZ administration (HR 1.05, 95% CI 1.00–1.09), and platelets (HR 0.27; 95% CI: 0.11, 0.69). In the post-TCZ analysis and compared to discharged patients, deceased patients had more lactate dehydrogenase (p 0.013), troponin I (p 0.013), C-reactive protein (p 0.013), neutrophils (p 0.024), and fewer platelets (p 0.013) and lymphocytes (p 0.013) as well as a lower average PaO2/FiO2 ratio. In conclusion, in COVID-19 diagnosed patients receiving TCZ, early treatment decreased the risk of death, while age, some comorbidities and baseline lower platelet counts increased that risk. After TCZ administration, lower platelet levels were again associated with mortality, together with other laboratory parameters. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Frontiers Research Foundation | es_ES |
dc.rights | Atribución 3.0 España | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject | COVID-19 | es_ES |
dc.subject | Immunosupression | es_ES |
dc.subject | Tocilizumab | es_ES |
dc.subject | Mortality | es_ES |
dc.subject | Risk factor | es_ES |
dc.subject | Platelet | es_ES |
dc.title | Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |
dc.identifier.doi | 10.3389/fphar.2021.620187 | |
dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es_ES |